Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
First Claim
1. A method of producing a sustained increase in dopamine uptake within one or both putamen in a human suffering from Parkinson'"'"'s disease that comprises locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein said GDNF protein product is administered in an amount and over a time effective to produce a sustained increase in dopamine uptake in the one or both putamen, and wherein the diffusion of said GDNF protein product resulting from such administration is limited to the putamen.
5 Assignments
0 Petitions
Accused Products
Abstract
A method of treating Parkinson'"'"'s disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof via convection-enhanced infusion using at least one implantable pump and at least one catheter. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal multiport brain catheters connected to one or more implantable pumps wherein the flow rate is pulsed.
44 Citations
43 Claims
- 1. A method of producing a sustained increase in dopamine uptake within one or both putamen in a human suffering from Parkinson'"'"'s disease that comprises locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein said GDNF protein product is administered in an amount and over a time effective to produce a sustained increase in dopamine uptake in the one or both putamen, and wherein the diffusion of said GDNF protein product resulting from such administration is limited to the putamen.
-
4. A method of producing a sustained increase in dopamine uptake within one or both putamen in a human suffering from Parkinson'"'"'s disease that comprises:
-
assessing dopaminergic function in one or both putamen of said human, pre-operatively; identifying at least one site of dopaminergic dysfunction within one or both putamen; locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein said GDNF protein product is administered in an amount and over a time effective to produce a sustained increase in dopamine uptake in the one or both putamen, and wherein the diffusion of said GDNF protein product resulting from such administration is limited to the putamen; and
,optionally, assessing dopaminergic function at one or more sites post-operatively, at least once. - View Dependent Claims (5, 6, 7, 8, 9)
-
- 10. A method of producing a sustained increase in dopamine uptake within one or both putamen, thereby increasing the function of dopaminergic neurons in a human in need thereof that comprises locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein said GDNF protein product is administered in an amount and over a time effective to produce a sustained increase in dopamine uptake in the one or both putamen, and wherein the diffusion of said GDNF protein product resulting from such administration is limited to the putamen.
- 15. A method of increasing the uptake of dopamine by dopaminergic neurons in a human that comprises locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein diffusion of said GDNF protein product is limited to the putamen of said human.
- 20. A method of regenerating dopaminergic neurons in a human that comprises locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein diffusion of said GDNF protein product is limited to the putamen of said human.
- 25. A method of protecting dopaminergic neurons susceptible to degeneration in a human that comprises locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein diffusion of said GDNF protein product is limited to the putamen of said human.
- 30. A method of treating Parkinson'"'"'s disease in a human that comprises locally administering to a region of one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein diffusion of said GDNF protein product is limited to the putamen of said human.
- 35. A method of treating Parkinson'"'"'s disease in a human that comprises locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein diffusion of said GDNF protein product is limited to the putamen of said human.
-
41. A method of producing a sustained increase in dopamine uptake within one or both putamen in a human suffering from Parkinson'"'"'s disease, said method consisting essentially of the step of locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein said GDNF protein product is administered in an amount and over a time effective to produce a sustained increase in dopamine uptake in the one or both putamen, and wherein the diffusion of said GDNF protein product resulting from such administration is limited to the putamen of said human.
-
42. A method of producing a sustained increase in dopamine uptake within one or both putamen in a human suffering from Parkinson'"'"'s disease, said method consisting of the step of locally administering to one or both putamen of a human in need thereof via convection-enhanced infusion using at least one catheter implanted for localized and targeted delivery into the putamen a pharmaceutical composition comprising a pharmaceutically effective amount of a glial cell-line derived neurotrophic factor (GDNF) protein product and at least one pharmaceutically acceptable vehicle, excipient, or diluent, wherein said GDNF protein product is administered in an amount and over a time effective to produce a sustained increase in dopamine uptake in the one or both putamen, and wherein the tissue distribution of said GDNF protein product resulting from such administration is limited to the putamen of said human.
Specification